# Use of Bleomycin in the Sclerotherapy of Lymphatic Malformations for Pediatric Patients

> **NCT06437158** · PHASE2 · RECRUITING · sponsor: **West China Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Lymphatic Malformation

## Interventions

- **DRUG:** Bleomycin

## Key facts

- **NCT ID:** NCT06437158
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-08
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06437158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06437158, "Use of Bleomycin in the Sclerotherapy of Lymphatic Malformations for Pediatric Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06437158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*